XOMA Royalty Corporation (XOMA)
(Delayed Data from NSDQ)
$29.25 USD
-0.25 (-0.85%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $29.27 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
XOMA Royalty (XOMA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$83.00 | $117.00 | $49.00 | 181.36% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for XOMA Royalty comes to $83.00. The forecasts range from a low of $49.00 to a high of $117.00. The average price target represents an increase of 181.36% from the last closing price of $29.50.
Analyst Price Targets (2 )
Broker Rating
XOMA Royalty currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, two are Strong Buy, representing 66.67% of all recommendations. A month ago, Strong Buy represented 66.67%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/XOMA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.67 | 1.67 | 1.67 | 1.67 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/15/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
4/29/2024 | SVB Securities | David Risinger | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Philip M Nadeau | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 3 |
Average Target Price | $83.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.44 |